Ultragenyx Pharmaceutical | RARE - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Immunic USD 3.45M 451K 2025-12
Insmed USD 247.26M 34.78M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Kyowa Hakko Kirin JPY 41.07B 2.82B 2026-03
MacroGenics USD 7.94M 1.96M 2025-12
Moderna USD 173M 135M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xoma USD 11M 2.54M 2024-06